Sustained inhibition of IL-6 and IL-8 expression by decoy ODN to NF-κB delivered through respirable large porous particles in LPS-stimulated cystic fibrosis bronchial cells

Journal of Gene Medicine

Volumn 13, Issue 4, 2011, Pages 200-208

  De Stefano, Daniela ^a   Ungaro, Francesca ^a   Giovino, Concetta ^a   Polimeno, Antonio ^a   Quaglia, Fabiana ^a   Carnuccio, Rosa ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cystic fibrosis; Decoy oligodeoxynucleotide; Dry powders; Nuclear factor B; P. aeruginosa LPS; Pulmonary delivery

Indexed keywords

DECOY OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MESSENGER RNA; OLIGODEOXYNUCLEOTIDE; POLYGLACTIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BRONCHUS MUCOSA; CELL STIMULATION; CONTROLLED STUDY; CYSTIC FIBROSIS; DENSITY; DNA BINDING; DRUG DELIVERY SYSTEM; DRUG EFFECT; EMULSION; EPITHELIUM CELL; GENE MUTATION; HUMAN; HUMAN CELL; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA;

ANALYSIS OF VARIANCE; BRONCHI; CELLS, CULTURED; CYSTIC FIBROSIS; DNA PRIMERS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; LIPOPOLYSACCHARIDES; NF-KAPPA B; OLIGODEOXYRIBONUCLEOTIDES; PSEUDOMONAS AERUGINOSA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS;

BACTERIA (MICROORGANISMS); PSEUDOMONAS AERUGINOSA;

EID: 79955161649     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1546     Document Type: Article

References (36)

1. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005; 352: 1992-2001.
2. Boncoeur E, Roque T, Bonvin E, et al. Cystic fibrosis transmembrane conductance regulator controls lung proteasomal degradation and nuclear factor-kappaB activity in conditions of oxidative stress. Am J Pathol 2008; 172: 1184-1194.
3. Downey DG, Bell SC, Elborn JS. Neutrophils in cystic fibrosis. Thorax 2009; 64: 81-88.
4. Greene CM, Carroll TP, Smith SG, et al. TLR-induced inflammation in cystic fibrosis and non-cystic fibrosis airway epithelial cells. J Immunol 2005; 174: 1638-1646.
5. Bonfield TL, Panuska JR, Konstan MW, et al. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995; 152: 2111-2118.
6. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995; 151: 1075-1082.
7. Noah TL, Wortman IA, Hu PC, Leigh MW, Boucher RC. Cytokine production by cultured human bronchial epithelial cells infected with a replication-deficient adenoviral gene transfer vector or wild-type adenovirus type 5. Am J Respir Cell Mol Biol 1996; 14: 417-424.
8. Weber AJ, Soong G, Bryan R, Saba S, Prince A. Activation of NF-kappaB in airway epithelial cells is dependent on CFTR trafficking and Cl-channel function. Am J Physiol Lung Cell Mol Physiol 2001; 281: L71-L78.
9. Verhaeghe C, Remouchamps C, Hennuy B, et al. Role of IKK and ERK pathways in intrinsic inflammation of cystic fibrosis airways. Biochem Pharmacol 2007; 73: 1982-1994.
10. Verhaeghe C, Delbecque K, de Leval L, Oury C, Bours V. Early inflammation in the airways of a cystic fibrosis foetus. J Cyst Fibros 2007; 6: 304-308.
11. Rottner M, Freyssinet JM, Martinez MC. Mechanisms of the noxious inflammatory cycle in cystic fibrosis. Respir Res 2009; 10: 23-34.
12. Venkatakrishnan A, Stecenko AA, King G, et al. Exaggerated activation of nuclear factor-kappaB and altered IkappaB-beta processing in cystic fibrosis bronchial epithelial cells. Am J Respir Cell Mol Biol 2000; 23: 396-403.
13. Courtois G, Gilmore TD. Mutations in the NF-kappaB signaling pathway: implications for human disease. Oncogene 2006; 25: 6831-6843.
14. Egashira K, Suzuki J, Ito H, Aoki M, Isobe M, Morishita R. Long-term follow up of initial clinical cases with NF-kappaB decoy oligodeoxynucleotide transfection at the site of coronary stenting. J Gene Med 2008; 10: 805-809.
15. Viedt C, Dechend R, Fei J, Hansch GM, Kreuzer J, Orth SR. MCP-1 induces inflammatory activation of human tubular epithelial cells: involvement of the transcription factors, nuclear factor-kappaB and activating protein-1. J Am Soc Nephrol 2002; 13: 1534-1547.
16. De Stefano D, De Rosa G, Maiuri MC, et al. Oligonucleotide decoy to NF-kappaB slowly released from PLGA microspheres reduces chronic inflammation in rat. Pharmacol Res 2009; 60: 33-40.
17. Densmore CL. Advances in noninvasive pulmonary gene therapy. Curr Drug Deliv 2006; 3: 55-63.
18. Ziady AG, Davis PB. Current prospects for gene therapy of cystic fibrosis. Curr Opin Pharmacol 2006; 6: 515-521.
19. Seguin RM, Ferrari N. Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2009; 18: 1505-1517.
20. Griesenbach U, Cassady RL, Cain RJ, du Bois RM, Geddes DM, Alton EW. Cytoplasmic deposition of NFkappaB decoy oligonucleotides is insufficient to inhibit bleomycin-induced pulmonary inflammation. Gene Ther 2002; 9: 1109-1115.
21. Griesenbach U, Scheid P, Hillery E, de Martin R, Huang L, Geddes DM, et al. Anti-inflammatory gene therapy directed at the airway epithelium. Gene Ther 2000; 7: 306-313.
22. Wijagkanalan W, Kawakami S, Higuchi Y, Yamashita F, Hashida M. Intratracheally instilled mannosylated cationic liposome/NFkappaB decoy complexes for effective prevention of LPS-induced lung inflammation. J Control Release 2011; 149: 42-50.
23. Rogueda PG, Traini D. The nanoscale in pulmonary delivery. Part 2: formulation platforms. Expert Opin Drug Deliv 2007; 4: 607-620.
24. Cryan SA. Carrier-based strategies for targeting protein and peptide drugs to the lungs. AAPS J 2005; 7: E20-E41.
25. Salama R, Traini D, Chan HK, Young PM. Recent advances in controlled release pulmonary therapy. Curr Drug Deliv 2009; 6: 404-414.
26. Mundargi RC, Babu VR, Rangaswamy V, et al. Nano/micro technologies for delivering macromolecular therapeutics using poly (D, L-lactide-co-glycolide) and its derivatives. J Control Release 2008; 125: 193-209.
27. Edwards DA, Ben-Jebria A, Langer R. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol 1998; 85: 379-385.
28. Ungaro F, d'Emmanuele di Villabianca R, Giovino C, et al. Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs. J Control Release 2009; 135: 25-34.
29. Ungaro F, De Rosa G, Miro A, Quaglia F, La Rotonda MI. Cyclodextrins in the production of large porous particles: development of dry powders for the sustained release of insulin to the lungs. Eur J Pharm Sci 2006; 28: 423-432.
30. De Rosa G, Maiuri MC, Ungaro F, et al. Enhanced intracellular uptake and inhibition of NF-kappaB activation by decoy oligonucleotide released from PLGA microspheres. J Gene Med 2005; 7: 771-781.
31. Ungaro F, Giovino C, Coletta C, Sorrentino R, Miro A, Quaglia F. Engineering gas-foamed large porous particles for efficient local delivery of macromolecules to the lung. Eur J Pharm Sci 2010; 41: 60-70.
32. DiMango E, Ratner AJ, Bryan R, Tabibi S, Prince A. Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells. J Clin Invest 1998; 101: 2598-2605.
33. Joseph T, Look D, Ferkol T. NF-kappaB activation and sustained IL-8 gene expression in primary cultures of cystic fibrosis airway epithelial cells stimulated with Pseudomonas aeruginosa. Am J Physiol Lung Cell Mol Physiol 2005; 288: L471-L479.
34. Machen TE. Innate immune response in CF airway epithelia: hyperinflammatory? Am J Physiol Cell Physiol 2006; 291: C218-C230.
35. Bezzerri V, Borgatti M, Nicolis E, et al. Transcription factor oligodeoxynucleotides to NF-kappaB inhibit transcription of IL-8 in bronchial cells. Am J Respir Cell Mol Biol 2008; 39: 86-96.
36. Loke SL, Stein CA, Zhang XH, et al. Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci USA 1989; 86: 3474-3478.